Company
Kalocyte
KaloCyte is developing ErythroMer™, a dried, bio-inspired artificial red blood cell, to treat life-threatening blood loss when stored red blood cells are unavailable, undesirable or in short supply.
Also known as KaloCyte, Inc.
- Status
- Operatingas of 2026-09-17Source (opens in a new tab)
- Headquarters
- Baltimore, MD, United States
- Founded
- 2016
- Employees
- Team expanded to 12 employeesSource (opens in a new tab)
- Legal name
- KaloCyte, Inc.
- kalocyte.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- Press page (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 17 September 2026
About
KaloCyte was founded by a distinguished team of researchers in physiology, bioengineering, and trauma care and is poised to deliver ErythroMer, a dried, bio-inspired artificial red blood cell, to market. ErythroMer is envisioned for use when stored red blood cells are unavailable, undesirable or in short supply. KaloCyte is supported by over $20M in federal grants and investor funding.
Funding snapshot
- Total raised
- $8.1MSum of rounds, as of 2026-09-17Source (opens in a new tab)
- Latest round
- Seed, $2.6M2025
Funding rounds
- Seed
- $2.6M2025, Company stated
- Bridge
- $700K2024, Company stated
- Bridge
- $1M2023, Company stated
- Convertible note
- $1M2022, Company stated
- Convertible note
- $1M2021, Company stated
- Convertible note
- $1M2020, Company stated
- Round, 2018
- $800K2018-04-27, SEC form D sold, 3 investors
- Seed
- $800K2018, Company stated
Products
- Other
- ErythroMer
Loading relationship preview